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Clinical Trials
Hyperoxemic Therapy Not Positive for Primary End Point
Experimental evidence suggests that supraphysiologic levels of oxygen may reducereperfusion injury by decreasing tissue edema and preventing the formation of
lipid peroxide radicals. The AMIHOT trial used a novel catheter-based system to
deliver bloodmixed with aqueous oxygen (AO) to the infarct-related artery in patients
treatedwith primary percutaneous coronary intervention. Subjects were eligible if they
had either an anterior ST-segment elevationmyocardial infarction (STEMI) or a large
inferior STEMI andhad24hof symptoms.Therewas nodifference in the incidence
of major adverse cardiac events at 30 days or in final infarct size at 14 days. A post-hoc
analysis suggests that patients with anterior MIs treated within 6 h of symptom onset
did better with AO. An accompanying editorial laments the lack of efficacy of strategies
designed to limit reperfusion injury. See pages 397 and 406. See figure.
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Statins and Toxicity
High-Dose Statins Associated With Increased Risk of Cancer
Alsheikh-Ali and colleagues pooled data from 23 trials with over 300,000 subject-years of data to compare the rates of elevated liver enzymes, rhabdomyolysis, and
incident cancer in patients treated with statins. Changes in low-density lipoprotein
(LDL) levels, as reflected in absolute LDL reductions, % LDL reduction, or achieved
LDL levels, all were unrelated to elevated liver enzyme levels or to rhabdomyolysis.
Higher doses of statins, on the other hand, were associatedwith elevated liver enzymes.
With new cancer cases, a worrying trend emerged. There was a significant relationship
between achieved LDL levels and new cancer cases. Two accompanying editorial
comments point out the considerations involved in the decision to publish the paper
and that the apparent increased risk of incident cancer should be considered
hypothesis-generating rather than conclusive because there was no particular type of
cancer that was increased and the relatively short duration of most of the studies
involved. See pages 409, 419, and 421. See figure.
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Heart Rhythm Disorders
Limited Efficacy of VT Ablation in Patients With ARVD
Patients with arrhythmogenic right ventricular dysplasia (ARVD) frequently expe-rience ventricular arrhythmias; those with implantable cardioverter-defibrillators
may receive frequent discharges that have encouraged some to consider catheter-based
ventricular tachycardia (VT) ablations. Dalal and colleagues reviewed the efficacy of
VT ablations in 24 patients who underwent a total of 48 ablation procedures. Proce-
dural success was reported in 46%, partial success in 31%, and failure in 23% of
patients.During follow-up,VT recurred after 85%of the procedures and in all but one
of the 24 patients. This study suggests that catheter-based ablation of VT for patients
with ARVD has limited long-term efficacy and should not be considered curative.
See page 432. See figure.
